We have 4 of 30 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Resistance to tyrosine kinase inhibitors (TKIs), particularly pazopanib, is the primary driver of treatment failure in patients with advanced clear cell renal cell carcinoma (ccRCC). However, the epitranscriptomic mechanisms underlying TKI resistance, especially the regulatory role of N6-methyladenosine (m6A) modificat...
Abstract Background Enzalutamide resistance in advanced prostate cancer often leads to treatment‐induced neuroendocrine prostate cancer (t‐NEPC), characterized by aggressive lineage plasticity. The molecular regulators governing neuroendocrine differentiation and phenotypic transition are not well understood. Here, we...
Pan-cancer analysis revealed that SH3BGRL3 expression was upregulated in most tumors, and correlated with unfavorable outcomes and advanced tumor stages of various cancers, and served as a promising prognostic and immunological biomarker exhibiting cancer-type-specific variations.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
